Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › ATHE

Alterity Therapeutics

ATHE Rare disease Lead: Phase 2 ★ Read the deep dive → 10 Biotech Distilled articles ↓ 87 filings & releases ↓ 10 verdicts ↓
Neurology Small Molecule

Market cap $46.4M 19.1M shares (vendor count, Nov 7, 2026) × $2.43 close Nov 6, 2026 · share count from the market-data vendor, not the SEC cover page

Most recent annual filing: 2026-08-28

Pipeline (2 active programs)

Technology platforms

Iron Chaperone Discovery Platform

Broad-spectrum platform targeting the interrelationship of metals and proteins in neurodegenerative and age-related diseases, including Parkinson's disease, Alzheimer's disease, Huntington disease, and potentially certain cancers, age-related macular degeneration, diabetes mellitus, and cardiovascular disease. Generates novel iron-modulating and zinc-modulating compounds from a chemical library of over 1000 validated compounds across diverse scaffolds.

Targets: labile iron, zinc, α-synuclein

Discontinued (2)

Capital (as filed)

As stated in coverage
A$37.3M cash per the update of Oct 5, 2026 — the company's own words as read there, not the filed figure; stated in AUD

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (10)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (10 calls)

Every verdict Biotech Distilled has published on Alterity Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-03-26 Watch Alterity Therapeutics (ATHE) - Scientific Deep Dive for ATH434 and Pipeline Products The 50mg Phase 2 signal is intriguing but the baseline imbalances and upcoming EOP2 FDA meeting make waiting for regulatory clarity the smartest play before taking a heavy position.
  2. 2026-04-27 Watch UPDATE: Alterity Therapeutics (ATHE) - The Regulatory Coil Tightens, and a New Scale Quietly Solves the 75mg Problem Three Type C green lights and MuSyCA replication strengthen the 50mg signal and narrow regulatory risk, but the stock is up 27.8% and the EOP2 binary is still pending, so accumulating only on weakness remains the stance.
  3. 2026-05-01 Buy UPDATE: Alterity Therapeutics (ATHE) - The FDA Says Yes (To The Easy Stuff) Three of four FDA disciplines are now green-lit, MuSyCA replicates the 50mg signal, and M&A signals are compounding, but the EOP2 binary on patient selection and primary endpoint is still pending — accumulate on any pre-EOP2 dip rather than chasing the 32% run.
  4. 2026-06-09 Buy core UPDATE: Alterity Therapeutics (ATHE) - The Binary Resolves Clean The EOP2 binary resolved on the bull side on every contested element — UMSARS Part I primary, 50mg BID, ~200 patients, single-dose design — retiring the regulatory bear case and leaving clinical replication and financing as the remaining risks.
  5. 2026-07-07 Buy core UPDATE: Alterity Therapeutics (ATHE) - The Minutes Say "One Trial" The official FDA EOP2 minutes confirm a single pivotal trial plus the existing Phase 2 as confirmatory evidence can support an NDA, materially shortening the timeline and capital requirement and strengthening M&A appeal.
  6. 2026-07-30 Buy core UPDATE: Alterity Therapeutics (ATHE) - The Runway Just Got Short The regulatory package is unchanged and the registration batch is manufactured, but cash has dropped to A$37.3M with burn accelerating to A$7.17M/quarter giving only 5.2 quarters of runway, making financing structure the dominant near-term variable.
  7. 2026-08-14 Buy core UPDATE: Alterity Therapeutics (ATHE) - A Better Hand to Play at the Negotiating Table A new USPTO composition-of-matter patent on the crystalline mesylate form of ATH434 extending to at least 2045 strengthens the asset being shopped in the structured process, but does not resolve the financing question.
  8. 2026-08-31 Buy core UPDATE: Alterity Therapeutics (ATHE) - The First Dollar Through the Door Is a Small One The option underwriting raises only A$4.2–7.96M — weeks of burn, not a pivotal-trial funding solution — leaving the structured partnership process as the unresolved key variable.
  9. 2026-10-06 Hold UPDATE: Alterity Therapeutics (ATHE) - The Footnote That Mattered More Than the Headline The pre-specified primary MRI iron endpoint was not met and the only significant imaging result went the wrong way, weakening the mechanistic leg of the thesis; the FDA-aligned pivotal path on UMSARS Part I is intact but the biomarker story is now murky, warranting a downgrade to HOLD pending the financing event.
  10. 2026-10-31 Hold UPDATE: Alterity Therapeutics (ATHE) - The 30.8-Quarter Mirage The headline 30.8-quarter runway is a one-time tax-refund artifact, the year-end Phase 3 initiation date has quietly disappeared from the release, and the structured partnership process remains unresolved after five quarters, keeping the stance at HOLD.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (87)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

1 more filing (13G holder notices, S-8, proxy material, SEC correspondence …)